Stargardt Disease clinical trials in Texas
10 active Stargardt Disease trials with a site in Texas. Describe your situation to see which ones you may be eligible for.
- A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
- Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
- Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
- A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
- Study of ALK-001 on the Progression of Stargardt Disease
- A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
- Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
- An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
- A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
- An Observational Study in Children and Adults With Stargardt Disease
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.